ArticleLeukemia research2018

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.

Yasmin Abaza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.